Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.68 USD

201.68
5,108,724

+1.21 (0.60%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie's (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.

Mark Vickery headshot

More Earnings, Data Following Big Tech Q2 Blowout: XOM, MRK, CAT & More

Markets finish out a busy week in the heart of Q2 earnings season with plenty of other leaders across a spectrum of industries, plus a few new economic reports.

Earnings & Economic Data Deluge

Earnings & Economic Data Deluge

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 4.46% and 2.99%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for AbbVie (ABBV)

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Amgen (AMGN) Stock Moves Lower Despite Q2 Earnings Beat

Amgen (AMGN) beats Q2 estimates for both earnings and sales. It maintains its previously-issued sales guidance while raising the earnings range. Stock dips.

Why the Earnings Surprise Streak Could Continue for AbbVie (ABBV)

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q2 Earnings?

AbbVie's (ABBV) Q2 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.

Want To Retire Early? Learn the Intelligent Investing Secret - July 28, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Sweta Killa headshot

What Lies Ahead for Healthcare ETFs in Q2 Earnings?

The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.

Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?

Is (ABBV) Outperforming Other Medical Stocks This Year?

3 Top Dividend Stocks to Maximize Your Retirement Income - July 27, 2020

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

How Damaging Will Coronavirus be for AbbVie (ABBV) Q2 Earnings?

Investor focus is likely to be on the impact of the coronavirus outbreak on AbbVie's (ABBV) performance when it reports second-quarter results.

Zacks.com featured highlights include: Quest Diagnostics, eBay, Cisco Systems, Cigna and AbbVie

Zacks.com featured highlights include: Quest Diagnostics, eBay, Cisco Systems, Cigna and AbbVie

Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

5 Coronavirus-Proof GARP Stocks to Pick on Discounted PEG

A lower PEG ratio, preferably less than 1, is always better for GARP investors.

Kinjel Shah headshot

Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data

Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.

Signs That Your Trading Will Ruin Your Retirement - July 24, 2020

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

Benjamin Rains headshot

3 Strong Dividend Stocks to Buy Now for Income & Coronavirus Growth

Let's dive into three stocks that are projected to grow during the pandemic that also provide solid income through dividends...

Pfizer (PFE) Looks Good: Stock Adds 5.1% in Session

Pfizer (PFE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AbbVie's Rinvoq Meets Late-Stage Eczema Study Endpoints

AbbVie's (ABBV) JAK inhibitor, Rinvoq monotherapy achieves improvement in skin clearance and reduction in itch in significantly higher proportion of atopic dermatitis patients in a phase III study.

Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker

Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.

Glaxo, CureVac to Develop mRNA Vaccines for Infectious Disease

Glaxo (GSK) signs a pact with CureVac for the development/commercialization of mRNA-based vaccines and monoclonal antibodies aimed at infectious disease pathogens.

Novartis' (NVS) Q2 Earnings Surpass Estimates, Sales Miss

Novartis' (NVS) second-quarter 2020 sales take a hit due to the coronavirus pandemic.